CRBP: CRB-701 delivers best-in-class efficacy and safety in HNSCC and cervical cancer, with pivotal trials ahead
Less than 1 min read
Three clinical-stage assets are advancing, with CRB-701 showing strong efficacy and safety in HNSCC and cervical cancer, outperforming competitors. CRB-913 demonstrates early, deepening weight loss with a favorable safety profile, and CRB-601 offers a novel approach to TGFB inhibition. Key data readouts and registrational studies are expected in 2025–2026.
Original document: Corbus Pharmaceuticals Holdings, Inc. [CRBP] Slides Release — Dec. 11 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr